Underwriter |
Biotech company (symbol) |
Date priced |
Offering price per share |
12/31/13 share price |
Offering gross (M) |
After-market |
Aegis Capital |
Aastrom Biosciences Inc.3 (Ann Arbor, Mich.; ASTM) (co-lead) |
8/14/13 |
$6.00 |
$3.23 |
$8.70 |
-46% |
Aegis Capital |
Advaxis Inc. (Princeton, N.J.; OTCQB:ADXS) |
10/17/13 |
$4.00 |
$4.24 |
$26.50 |
6% |
Aegis Capital |
Alcobra Ltd. (Tel Aviv, Israel; ADHD) (co-lead) |
10/25/13 |
$16.50 |
$18.00 |
$37.95 |
9% |
Aegis Capital |
Alcobra Ltd. (Tel Aviv, Israel; ADHD) (lead) (IPO) |
5/22/13 |
$8.00 |
$18.00 |
$25.00 |
125% |
Aegis Capital |
Cytrx Corp. (Los Angeles; CYTR) (lead) |
10/10/13 |
$2.25 |
$6.27 |
$25.90 |
179% |
Aegis Capital |
Evoke Pharma Inc. (San Diego; EVOK) (IPO) (lead) |
9/25/13 |
$12.00 |
$7.45 |
$28.98 |
-38% |
Aegis Capital |
Heat Biologics (Chapel Hill, N.C.; HTBX) (lead) (IPO) |
7/24/13 |
$10.00 |
$7.10 |
$25.00 |
-29% |
Aegis Capital |
Imprimis Pharmaceuticals Inc. (Solana Beach, Calif.; IMMY) (co-lead) |
2/11/13 |
$5.25 |
$3.36 |
$9.66 |
-36% |
Aegis Capital |
Neostem Inc. (New York; NBS) (lead) |
10/4/13 |
$7.00 |
$6.82 |
$40.25 |
-3% |
Aegis Capital |
Neostem Inc.4 (New York; NYSE:NBS) (lead) |
4/30/13 |
$5.00 |
$6.82 |
$10.75 |
36% |
Aegis Capital |
Oculus Innovative Sciences Inc.5 (Petaluma, Calif.; OCLS) (lead) |
3/7/13 |
$2.80 |
$3.48 |
$3.45 |
24% |
Aegis Capital |
Opexa Therapeutics Inc. (The Woodlands, Texas; OPXA) (lead) |
8/8/13 |
$1.50 |
$1.82 |
$18.98 |
21% |
Aegis Capital |
Opexa Therapeutics Inc. (The Woodlands, Texas; OPXA) (lead) |
12/18/13 |
$1.70 |
$1.82 |
$7.00 |
7% |
Aegis Capital |
Sorrento Therapeutics Inc. (San Diego; SRNE) (lead) |
10/28/13 |
$7.25 |
$8.10 |
$34.58 |
12% |
Aegis Capital |
Stemline Therapeutics Inc. (New York; STML) (lead) (IPO) |
1/29/13 |
$10.00 |
$19.60 |
$38.20 |
96% |
Aegis Capital |
Synthetic Biologics Inc. (Rockville, Md.; NYSE:SYN) (lead) |
12/13/13 |
$1.00 |
$1.53 |
$13.23 |
53% |
Ascendiant Capital |
Repros Therapeutics Inc. (The Woodlands, Texas; RPRX) |
6/20/13 |
$19.00 |
$18.30 |
$81.94 |
-4% |
Baird |
Ambit Biosciences Inc. (San Diego; AMBI) (IPO) |
5/16/13 |
$8.00 |
$9.64 |
$65.00 |
21% |
Baird |
Cerus Corp. (Concord, Calif.; CERS) |
3/14/13 |
$4.20 |
$6.45 |
$35.00 |
54% |
Baird |
Tesaro Inc. (Waltham, Mass.; TSRO) |
3/1/13 |
$18.00 |
$28.24 |
$97.20 |
57% |
Baird |
Trius Therapeutics Inc.7 (San Diego; TSRX) (co-lead) |
1/18/13 |
$4.75 |
$13.63 |
$34.20 |
187% |
Bank of America Merrill Lynch |
Bluebird Bio Inc. (Cambridge, Mass.; BLUE) (co-lead) (IPO) |
6/19/13 |
$17.00 |
$20.98 |
$116.11 |
23% |
Bank of America Merrill Lynch |
Durata Therapeutics Inc. (Chicago; DRTX) (co-lead) |
4/12/13 |
$7.00 |
$12.79 |
$50.05 |
83% |
Bank of America Merrill Lynch |
Intercept Pharmaceuticals Inc. (New York; ICPT) (co-lead) |
6/19/13 |
$33.01 |
$68.28 |
$65.69 |
107% |
Bank of America Merrill Lynch |
Ironwood Pharmaceuticals Inc. (Cambridge, Mass.; IRWD) (co-lead) |
5/22/13 |
$13.00 |
$11.61 |
$145.60 |
-11% |
Bank of America Merrill Lynch |
Karyopharm Therapeutics Inc. (Natick, Mass.; KPTI) (co-lead) (IPO) |
11/7/13 |
$16.00 |
$22.92 |
$125.12 |
43% |
Bank of America Merrill Lynch |
Kythera Biopharmaceuticals Inc. (Calabasas, Calif.; KYTH) (co-lead) |
10/9/13 |
$45.75 |
$37.35 |
$120.00 |
-18% |
Bank of America Merrill Lynch |
Macrogenics Inc. (Rockville, Md.; MGNX) (co-lead) (IPO) |
10/11/13 |
$16.00 |
$27.43 |
$92.00 |
71% |
Bank of America Merrill Lynch |
Omthera Pharmaceuticals Inc.2 (Princeton, N.J.; OMTH) (co-lead) (IPO) |
4/12/13 |
$8.00 |
$12.70 |
$64.00 |
59% |
Bank of America Merrill Lynch |
Onyx Pharmaceuticals Inc.8 (South San Francisco; ONXX) (co-lead) |
1/16/13 |
$81.50 |
$125.00 |
$358.60 |
53% |
Bank of America Merrill Lynch |
Prothena Corp. plc (Dublin; PRTA) (co-lead) |
10/13/13 |
$22.00 |
$26.52 |
$77.00 |
21% |
Bank of America Merrill Lynch |
Relypsa Inc. (Redwood City, Calif.; RLYP) (co-lead) (IPO) |
11/15/13 |
$11.00 |
$25.00 |
$85.80 |
127% |
Bank of America Merrill Lynch |
Repros Therapeutics Inc. (The Woodlands, Texas; RPRX) (lead) |
6/20/13 |
$19.00 |
$18.30 |
$81.94 |
-4% |
Bank of America Merrill Lynch |
Sagent Pharmaceuticals Inc. (Schaumburg, Ill.; SGNT) (co-lead) |
9/11/13 |
$21.25 |
$25.38 |
$75.28 |
19% |
Barclays Capital |
Cempra Inc. (Chapel Hill, N.C.; CEMP) (co-lead) |
6/14/13 |
$7.00 |
$12.39 |
$57.75 |
77% |
Barclays Capital |
Fibrocell Science Inc. (Exton, Pa.; FCSC) (co-lead) |
9/26/13 |
$4.10 |
$4.06 |
$50.43 |
-1% |
Barclays Capital |
Keryx Biopharmaceuticals Inc. (New York; KERX) |
1/31/13 |
$8.49 |
$12.95 |
$69.90 |
53% |
Barclays Capital |
Omthera Pharmaceuticals Inc.2 (Princeton, N.J.; OMTH) (co-lead) (IPO) |
4/12/13 |
$8.00 |
$12.70 |
$64.00 |
59% |
Barclays Capital |
Onyx Pharmaceuticals Inc.8 (South San Francisco; ONXX) (co-lead) |
1/16/13 |
$81.50 |
$125.00 |
$358.60 |
53% |
Barclays Capital |
Tetraphase Pharmaceuticals Inc. (Watertown, Mass.; TTPH) (co-lead) (IPO) |
3/20/13 |
$7.00 |
$13.52 |
$80.58 |
93% |
BMO Capital |
Ambit Biosciences Inc. (San Diego; AMBI) (IPO) |
5/16/13 |
$8.00 |
$9.64 |
$65.00 |
21% |
BMO Capital |
Ariad Pharmaceuticals Inc. (Cambridge, Mass.; ARIA) |
1/24/13 |
$19.60 |
$6.82 |
$323.40 |
-65% |
BMO Capital |
Fate Therapeutics Inc. (San Diego; FATE) (co-lead) (IPO) |
10/1/13 |
$6.00 |
$6.28 |
$46.20 |
5% |
BMO Capital |
Five Prime Therapeutics Inc. (South San Francisco; FPRX) (co-lead) (IPO) |
9/18/13 |
$13.00 |
$16.79 |
$71.80 |
29% |
BMO Capital |
Intercept Pharmaceuticals Inc. (New York; ICPT) (co-lead) |
6/19/13 |
$33.01 |
$68.28 |
$65.69 |
107% |
BMO Capital |
Isis Pharmaceuticals Inc. (Carlsbad, Calif.; ISIS) |
5/9/13 |
$19.00 |
$39.84 |
$182.70 |
110% |
BMO Capital |
Oncomed Pharmaceuticals Inc. (Redwood City, Calif.; OMED) (IPO) |
7/18/13 |
$17.00 |
$29.52 |
$93.50 |
74% |
BMO Capital |
Receptos Inc. (San Diego; RCPT) (co-lead) (IPO) |
5/9/13 |
$14.00 |
$28.99 |
$72.80 |
107% |
BMO Capital |
Regado Biosciences Inc. (Basking Ridge, N.J.; RGDO) (co-lead) (IPO) |
8/22/13 |
$4.00 |
$4.77 |
$46.68 |
19% |
BMO Capital |
Regulus Therapeutics Inc. (La Jolla, Calif.; RGLS) (co-lead) |
7/17/13 |
$9.50 |
$7.39 |
$49.20 |
-22% |
BMO Capital |
Tesaro Inc. (Waltham, Mass.; TSRO) |
3/1/13 |
$18.00 |
$28.24 |
$97.20 |
57% |
BMO Capital |
Tetraphase Pharmaceuticals Inc. (Watertown, Mass.; TTPH) (co-lead) (IPO) |
3/20/13 |
$7.00 |
$13.52 |
$80.58 |
93% |
BMO Capital |
Tetraphase Pharmaceuticals Inc. (Watertown, Mass; TTPH) (co-lead) |
11/4/13 |
$10.00 |
$13.52 |
$49.00 |
35% |
Brean Capital |
A.P. Pharma Inc. (Redwood City, Calif.; OTCBB:APPA) |
11/21/13 |
$0.40 |
$0.45 |
$60.00 |
13% |
Brean Capital |
Celldex Therapeutics Inc. (Hampton, N.J.; CLDX) |
12/5/13 |
$24.50 |
$24.21 |
$191.40 |
-1% |
Brean Capital |
Celldex Therapeutics Inc. (Needham, Mass.; CLDX) |
2/6/13 |
$7.50 |
$24.21 |
$103.50 |
223% |
Brean Capital |
Inovio Pharmaceuticals Inc. (Blue Bell, Pa.; NYSE:INO) |
3/7/13 |
$0.55 |
$2.90 |
$15.06 |
427% |
Brean Capital |
Intellipharmaceutics International Inc. (Toronto; IPCI) |
8/1/13 |
$2.05 |
$3.71 |
$3.10 |
81% |
Brean Capital |
Keryx Biopharmaceuticals Inc. (New York; KERX) |
1/31/13 |
$8.49 |
$12.95 |
$69.90 |
53% |
Brean Capital |
Progenics Pharmaceuticals Inc. (Tarrytown, N.Y.; PGNX) |
6/21/13 |
$4.40 |
$5.33 |
$37.40 |
21% |
Brean Capital |
Synta Pharmaceuticals Corp. (Lexington, Mass.; SNTA) |
11/14/13 |
$3.75 |
$5.24 |
$60.38 |
40% |
Brean Capital |
TG Therapeutics Inc. (New York; TGTX) (co-lead) |
7/18/13 |
$6.15 |
$3.90 |
$35.10 |
-37% |
Burrill Securities |
Novavax Inc. (Rockville, Md.; NVAX) |
9/24/13 |
$3.14 |
$5.12 |
$99.85 |
63% |
Burrill Securities |
Novelos Therapeutics Inc. (Madison, Wis.; NVLT) (co-lead) |
2/14/13 |
$0.50 |
$0.37 |
$5.50 |
-26% |
C&Co./Princeridge |
Rockwell Medical Inc. (Wixom, Mich.; RMTI) |
5/15/13 |
$3.05 |
$10.44 |
$40.30 |
242% |
Canaccord Genuity |
Aegerion Pharmaceuticals Inc. (Cambridge, Mass.; AEGR) |
1/14/13 |
$26.64 |
$70.96 |
$72.05 |
166% |
Canaccord Genuity |
Aerie Pharmaceuticals Inc. (Bedminster, N.J.; AERI) (IPO) |
10/28/13 |
$10.00 |
$17.96 |
$77.20 |
80% |
Canaccord Genuity |
Aeterna Zentaris Inc. (Quebec City; AEZS) (lead) |
11/20/13 |
$1.15 |
$1.38 |
$15.00 |
20% |
Canaccord Genuity |
Anacor Pharmaceuticals Inc. (Palo Alto, Calif.; ANAC) |
4/26/13 |
$6.39 |
$16.78 |
$23.00 |
163% |
Canaccord Genuity |
Aveo Oncology Inc. (Cambridge, Mass.; AVEO) |
1/17/13 |
$7.50 |
$1.83 |
$57.75 |
-76% |
Canaccord Genuity |
Bluebird Bio Inc. (Cambridge, Mass.; BLUE) (IPO) |
6/19/13 |
$17.00 |
$20.98 |
$116.11 |
23% |
Canaccord Genuity |
GW Pharma plc (Wilshire, UK; GWPH) (IPO) |
5/1/13 |
$8.90 |
$41.54 |
$31.15 |
367% |
Canaccord Genuity |
Insmed Inc. (Monmouth Junction, N.J.; INSM) |
7/17/13 |
$10.40 |
$17.00 |
$62.40 |
63% |
Canaccord Genuity |
Intermune Inc. (Brisbane, Calif.; ITMN) |
1/16/13 |
$9.90 |
$14.73 |
$133.65 |
49% |
Canaccord Genuity |
Mast Therapeutics Inc. (San Diego; MSTX) (co-lead) |
6/14/13 |
$0.50 |
$0.46 |
$25.00 |
-8% |
Canaccord Genuity |
Mimedx Group Inc. (Marietta, Ga.; MDXG) (co-lead) |
12/12/13 |
$6.80 |
$8.74 |
$34.00 |
29% |
Canaccord Genuity |
Newlink Genetics Corp. (Ames, Iowa; NLNK) |
1/31/13 |
$11.40 |
$22.01 |
$52.44 |
93% |
Canaccord Genuity |
NPS Pharmaceuticals Inc. (Bedminster, N.J.; NPSP) |
5/20/13 |
$14.53 |
$30.36 |
$100.26 |
109% |
Canaccord Genuity |
Regado Biosciences Inc. (Basking Ridge, N.J.; RGDO) (IPO) |
8/22/13 |
$4.00 |
$4.77 |
$46.68 |
19% |
Canaccord Genuity |
Synageva Biopharma Corp. (Lexington, Mass.; GEVA) |
9/25/13 |
$56.63 |
$64.72 |
$178.95 |
14% |
Canaccord Genuity |
Synageva Biopharma Corp. (Lexington, Mass.; GEVA) |
1/3/13 |
$47.53 |
$64.72 |
$118.83 |
36% |
Canaccord Genuity |
Synergy Pharmaceuticals Inc. (New York; SGYP) |
4/9/13 |
$5.50 |
$5.63 |
$90.00 |
2% |
Canaccord Genuity |
Xoma Corp. (Berkeley, Calif.; XOMA) (co-lead) |
8/20/13 |
$3.62 |
$6.73 |
$31.50 |
86% |
Cantor Fitzgerald |
Apricus Biosciences Inc. (San Diego; APRI) |
5/24/13 |
$2.85 |
$2.65 |
$17.10 |
-7% |
Cantor Fitzgerald |
Celldex Therapeutics Inc. (Hampton, N.J.; CLDX) |
12/5/13 |
$24.50 |
$24.21 |
$191.40 |
-1% |
Cantor Fitzgerald |
Evoke Pharma Inc. (San Diego; EVOK) (IPO) |
9/25/13 |
$12.00 |
$7.45 |
$28.98 |
-38% |
Cantor Fitzgerald |
Heat Biologics (Chapel Hill, N.C.; HTBX) (IPO) |
7/24/13 |
$10.00 |
$7.10 |
$25.00 |
-29% |
Cantor Fitzgerald |
Newlink Genetics Corp. (Ames, Iowa; NLNK) |
1/31/13 |
$11.40 |
$22.01 |
$52.44 |
93% |
Cantor Fitzgerald |
Verastem Inc. (Cambridge, Mass.; VSTM) |
7/18/13 |
$15.00 |
$11.40 |
$64.50 |
-24% |
Chardan Capital Markets |
Cel-Sci Corp. (Vienna, Va.; NYSE Amex:CVM) (co-lead) |
10/9/13 |
$1.00 |
$0.59 |
$17.80 |
-41% |
Chardan Capital Markets |
Rockwell Medical Inc. (Wixom, Mich.; RMTI) (lead) |
5/15/13 |
$3.05 |
$10.44 |
$40.30 |
242% |
Chardan Capital Markets |
Stemcells Inc. (Newark, Calif.; STEM) (co-lead) |
10/2/13 |
$1.45 |
$1.23 |
$18.63 |
-15% |
Citigroup |
Acceleron Pharma Inc. (Cambridge, Mass.; XLRN) (co-lead) (IPO) |
9/19/13 |
$15.00 |
$39.60 |
$96.26 |
164% |
Citigroup |
Achillion Pharmaceuticals Inc. (New Haven, Conn.; ACHN) (co-lead) |
3/1/13 |
$8.40 |
$3.32 |
$141.96 |
-60% |
Citigroup |
Amarin Corp. plc (Dublin; AMRN) (co-lead) |
7/10/13 |
$5.60 |
$1.97 |
$121.52 |
-65% |
Citigroup |
Ambit Biosciences Inc. (San Diego; AMBI) (co-lead) (IPO) |
5/16/13 |
$8.00 |
$9.64 |
$65.00 |
21% |
Citigroup |
Epizyme Inc. (Cambridge, Mass.; EPZM) (co-lead) (IPO) |
5/31/13 |
$15.00 |
$20.80 |
$88.70 |
39% |
Citigroup |
Esperion Therapeutics Inc. (Plymouth, Mich.; ESPR) (co-lead) (IPO) |
6/26/13 |
$14.00 |
$13.74 |
$80.50 |
-2% |
Citigroup |
Intercept Pharmaceuticals Inc. (New York; ICPT) (co-lead) |
6/19/13 |
$33.01 |
$68.28 |
$65.69 |
107% |
Citigroup |
Keryx Biopharmaceuticals Inc. (New York; KERX) |
1/31/13 |
$8.49 |
$12.95 |
$69.90 |
53% |
Citigroup |
Onconova Therapeutics Inc. (Newtown, Pa.; ONTX) (co-lead) (IPO) |
7/25/13 |
$15.00 |
$11.48 |
$88.50 |
-23% |
Citigroup |
Prosensa Holding BV (Leiden, the Netherlands; RNA) (co-lead) (IPO) |
6/28/13 |
$13.00 |
$4.67 |
$89.70 |
-64% |
Citigroup |
Sophiris Bio Inc. (San Diego; SPHS) (co-lead) (IPO) |
8/16/13 |
$5.00 |
$3.70 |
$65.00 |
-26% |
Citigroup |
Synergy Pharmaceuticals Inc. (New York; SGYP) |
4/9/13 |
$5.50 |
$5.63 |
$90.00 |
2% |
Citigroup |
Tesaro Inc. (Waltham, Mass.; TSRO) (co-lead) |
3/1/13 |
$18.00 |
$28.24 |
$97.20 |
57% |
Citigroup |
Trius Therapeutics Inc.7 (San Diego; TSRX) (co-lead) |
1/18/13 |
$4.75 |
$13.63 |
$34.20 |
187% |
Cowen & Co. |
Acadia Pharmaceuticals Inc. (San Diego; ACAD) (co-lead) |
5/15/13 |
$12.50 |
$24.99 |
$115.00 |
100% |
Cowen & Co. |
Aegerion Pharmaceuticals Inc. (Cambridge, Mass.; AEGR) |
1/14/13 |
$26.64 |
$70.96 |
$72.05 |
166% |
Cowen & Co. |
Bind Therapeutics Inc. (Cambridge, Mass.; BIND) (co-lead) (IPO) |
9/20/13 |
$15.00 |
$15.09 |
$70.50 |
1% |
Cowen & Co. |
Dyax Corp. (Burlington, Mass.; DYAX) |
10/10/13 |
$6.50 |
$7.54 |
$60.00 |
16% |
Cowen & Co. |
Dynavax Technologies Corp. (Berkeley, Calif.; DVAX) (lead) |
10/25/13 |
$1.08 |
$1.96 |
$132.20 |
82% |
Cowen & Co. |
Kythera Biopharmaceuticals Inc. (Calabasas, Calif.; KYTH) |
10/9/13 |
$45.75 |
$37.35 |
$120.00 |
-18% |
Cowen & Co. |
Mei Pharma Inc. (San Diego; MEIP) (co-lead) |
10/28/13 |
$8.00 |
$8.01 |
$35.00 |
0% |
Cowen & Co. |
Portola Pharmaceuticals Inc. (South San Francisco; PTLA) |
10/17/13 |
$23.75 |
$25.75 |
$105.90 |
8% |
Cowen & Co. |
Regado Biosciences Inc. (Basking Ridge, N.J.; RGDO) (co-lead) (IPO) |
8/22/13 |
$4.00 |
$4.77 |
$46.68 |
19% |
Cowen & Co. |
Relypsa Inc. (Redwood City, Calif.; RLYP) (IPO) |
11/15/13 |
$11.00 |
$25.00 |
$85.80 |
127% |
Cowen & Co. |
Sangamo Biosciences Inc. (Richmond, Calif.; SGMO) |
9/19/13 |
$10.58 |
$13.89 |
$74.22 |
31% |
Cowen & Co. |
Synageva Biopharma Corp. (Lexington, Mass.; GEVA) |
9/25/13 |
$56.63 |
$64.72 |
$178.95 |
14% |
Cowen & Co. |
Xoma Corp. (Berkeley, Calif.; XOMA) (co-lead) |
8/20/13 |
$3.62 |
$6.73 |
$31.50 |
86% |
Cowen & Co. |
Agios Pharmaceuticals Inc. (Cambridge, Mass.; AGIO) (IPO) |
7/24/13 |
$18.00 |
$23.95 |
$120.60 |
33% |
Cowen & Co. |
Anacor Pharmaceuticals Inc. (Palo Alto, Calif.; ANAC) (lead) |
4/26/13 |
$6.39 |
$16.78 |
$23.00 |
163% |
Cowen & Co. |
Ariad Pharmaceuticals Inc. (Cambridge, Mass.; ARIA) (co-lead) |
1/24/13 |
$19.60 |
$6.82 |
$323.40 |
-65% |
Cowen & Co. |
Bluebird Bio Inc. (Cambridge, Mass.; BLUE) (IPO) |
6/19/13 |
$17.00 |
$20.98 |
$116.11 |
23% |
Cowen & Co. |
Cempra Inc. (Chapel Hill, N.C.; CEMP) (co-lead) |
6/14/13 |
$7.00 |
$12.39 |
$57.75 |
77% |
Cowen & Co. |
Cerus Corp. (Concord, Calif.; CERS) (lead) |
3/14/13 |
$4.20 |
$6.45 |
$35.00 |
54% |
Cowen & Co. |
Chemocentryx Inc. (Mountain View, Calif.; CCXI) |
4/17/13 |
$12.00 |
$5.79 |
$60.00 |
-52% |
Cowen & Co. |
Chimerix Inc. (Research Triangle Park, N.C.; CMRX) (co-lead) (IPO) |
4/11/13 |
$14.00 |
$15.11 |
$102.50 |
8% |
Cowen & Co. |
Epizyme Inc. (Cambridge, Mass.; EPZM) (co-lead) (IPO) |
5/31/13 |
$15.00 |
$20.80 |
$88.70 |
39% |
Cowen & Co. |
Fate Therapeutics Inc. (San Diego; FATE) (co-lead) (IPO) |
10/1/13 |
$6.00 |
$6.28 |
$46.20 |
5% |
Cowen & Co. |
GW Pharma plc (Wilshire, UK; GWPH) (co-lead) (IPO) |
5/1/13 |
$8.90 |
$41.54 |
$31.15 |
367% |
Cowen & Co. |
Hyperion Therapeutics Inc. (South San Francisco; HPTX) (co-lead) |
3/8/13 |
$20.75 |
$20.22 |
$67.00 |
-3% |
Cowen & Co. |
Immunomedics Inc. (Morris Plains, N.J.; IMMU) (co-lead) |
2/22/13 |
$2.30 |
$4.60 |
$14.00 |
100% |
Cowen & Co. |
Inovio Pharmaceuticals Inc. (Blue Bell, Pa.; NYSE:INO) (lead) |
3/7/13 |
$0.55 |
$2.90 |
$15.06 |
427% |
Cowen & Co. |
Ironwood Pharmaceuticals Inc. (Cambridge, Mass.; IRWD) |
5/22/13 |
$13.00 |
$11.61 |
$145.60 |
-11% |
Cowen & Co. |
Isis Pharmaceuticals Inc. (Carlsbad, Calif.; ISIS) |
5/9/13 |
$19.00 |
$39.84 |
$182.70 |
110% |
Cowen & Co. |
Mei Pharma Inc. (San Diego; MEIP) (co-lead) |
4/5/13 |
$7.50 |
$8.01 |
$15.20 |
7% |
Cowen & Co. |
Portola Pharmaceuticals Inc. (South San Francisco; PTLA) (IPO) |
5/22/13 |
$14.50 |
$25.75 |
$122.10 |
78% |
Cowen & Co. |
PTC Therapeutics Inc. (South Plainfield, N.J.; PTCT) (IPO) |
6/20/13 |
$15.00 |
$16.97 |
$144.48 |
13% |
Cowen & Co. |
Regulus Therapeutics Inc. (La Jolla, Calif.; RGLS) (co-lead) |
7/17/13 |
$9.50 |
$7.39 |
$49.20 |
-22% |
Cowen & Co. |
Synageva Biopharma Corp. (Lexington, Mass.; GEVA) |
1/3/13 |
$47.53 |
$64.72 |
$118.83 |
36% |
Cowen & Co. |
Xoma Corp. (Berkeley, Calif.; XOMA) |
12/13/13 |
$5.25 |
$6.73 |
$57.23 |
28% |
Craig Hallum Capital Group |
Mimedx Group Inc. (Marietta, Ga.; MDXG) (co-lead) |
12/12/13 |
$6.80 |
$8.74 |
$34.00 |
29% |
Credit Suisse |
Bind Therapeutics Inc. (Cambridge, Mass.; BIND) (co-lead) (IPO) |
9/20/13 |
$15.00 |
$15.09 |
$70.50 |
1% |
Credit Suisse |
Portola Pharmaceuticals Inc. (South San Francisco; PTLA) (co-lead) |
10/17/13 |
$23.75 |
$25.75 |
$105.90 |
8% |
Credit Suisse |
Prothena Corp. plc (Dublin; PRTA) (co-lead) |
10/13/13 |
$22.00 |
$26.52 |
$77.00 |
21% |
Credit Suisse |
Clovis Oncology Inc. (Boulder, Colo.; CLVS) (co-lead) |
6/12/13 |
$72.00 |
$60.27 |
$275.00 |
-16% |
Credit Suisse |
Durata Therapeutics Inc. (Chicago; DRTX) (co-lead) |
4/12/13 |
$7.00 |
$12.79 |
$50.05 |
83% |
Credit Suisse |
Enanta Pharmaceuticals Inc. (Watertown, Mass.; ENTA) (co-lead) (IPO) |
3/21/13 |
$14.00 |
$27.28 |
$64.40 |
95% |
Credit Suisse |
Esperion Therapeutics Inc. (Plymouth, Mich.; ESPR) (co-lead) (IPO) |
6/26/13 |
$14.00 |
$13.74 |
$80.50 |
-2% |
Credit Suisse |
Portola Pharmaceuticals Inc. (South San Francisco; PTLA) (co-lead) (IPO) |
5/22/13 |
$14.50 |
$25.75 |
$122.10 |
78% |
Credit Suisse |
PTC Therapeutics Inc. (South Plainfield, N.J.; PTCT) (co-lead) (IPO) |
6/20/13 |
$15.00 |
$16.97 |
$144.48 |
13% |
Credit Suisse |
Receptos Inc. (San Diego; RCPT) (co-lead) (IPO) |
5/9/13 |
$14.00 |
$28.99 |
$72.80 |
107% |
Credit Suisse |
Synergy Pharmaceuticals Inc. (New York; SGYP) (lead) |
4/9/13 |
$5.50 |
$5.63 |
$90.00 |
2% |
Credit Suisse |
Xencor Inc. (Redwood City, Calif.; XNCR) (co-lead) (IPO) |
12/3/13 |
$5.50 |
$9.14 |
$80.30 |
66% |
Credit Suisse |
Xoma Corp. (Berkeley, Calif.; XOMA) (co-lead) |
12/13/13 |
$5.25 |
$6.73 |
$57.23 |
28% |
CRT Capital |
Adamis Pharmaceuticals Corp. (San Diego; ADMP) (lead) |
12/16/13 |
$5.95 |
$6.39 |
$22.00 |
7% |
CRT Capital |
Sorrento Therapeutics Inc. (San Diego; SRNE) |
10/28/13 |
$7.25 |
$8.10 |
$34.58 |
12% |
Dawson James |
Arca Biopharma Inc. (Broomfield, Colo.; ABIO)12 |
5/30/13 |
$1.60 |
$1.68 |
$20.00 |
5% |
Dawson James |
Arrowhead Research Corp. (Pasadena, Calif.; ARWR) (lead) |
1/25/13 |
$2.12 |
$10.85 |
$3.50 |
412% |
Dawson James |
Cel-Sci Corp. (Vienna, Va.; NYSE:CVM) (co-lead) |
12/20/13 |
$0.63 |
$0.59 |
$3.30 |
-6% |
Dawson James |
Novelos Therapeutics Inc. (Madison, Wis.; NVLT) (co-lead) |
2/14/13 |
$0.50 |
$0.37 |
$5.50 |
-26% |
Dawson James |
Oculus Innovative Sciences Inc.5 (Petaluma, Calif.; OCLS) |
3/7/13 |
$2.80 |
$3.48 |
$3.45 |
24%
|
Dawson James |
Tonix Pharmaceuticals Holding Corp. (New York; TNXP) |
8/9/13 |
$4.25 |
$10.31 |
$11.39 |
143% |
Deutsche Bank Securities |
Alnylam Pharmaceuticals Inc. (Cambridge, Mass.; ALNY) |
1/16/13 |
$20.13 |
$64.30 |
$185.20 |
219% |
Deutsche Bank Securities |
Tesaro Inc. (Waltham, Mass.; TSRO) |
3/1/13 |
$18.00 |
$28.24 |
$97.20 |
57% |
Feltl & Co. |
Alcobra Ltd. (Tel Aviv, Israel; ADHD) (IPO) |
5/22/13 |
$8.00 |
$18.00 |
$25.00 |
125% |
Feltl & Co. |
Evoke Pharma Inc. (San Diego; EVOK) (IPO) |
9/25/13 |
$12.00 |
$7.45 |
$28.98 |
-38% |
Goldman Sachs & Co. |
Agios Pharmaceuticals Inc. (Cambridge, Mass.; AGIO) (co-lead) (IPO) |
7/24/13 |
$18.00 |
$23.95 |
$120.60 |
33% |
Goldman Sachs & Co. |
Chemocentryx Inc. (Mountain View, Calif.; CCXI) (co-lead) |
4/17/13 |
$12.00 |
$5.79 |
$60.00 |
-52% |
Goldman Sachs & Co. |
Intermune Inc. (Brisbane, Calif.; ITMN) (co-lead) |
11/6/13 |
$13.00 |
$14.73 |
$84.50 |
13% |
Goldman Sachs & Co. |
Intermune Inc. (Brisbane, Calif.; ITMN) (co-lead) |
1/16/13 |
$9.90 |
$14.73 |
$133.65 |
49% |
Goldman Sachs & Co. |
Isis Pharmaceuticals Inc. (Carlsbad, Calif.; ISIS) (co-lead) |
5/9/13 |
$19.00 |
$39.84 |
$182.70 |
110% |
Goldman Sachs & Co. |
Synageva Biopharma Corp. (Lexington, Mass.; GEVA) (lead) |
9/25/13 |
$56.63 |
$64.72 |
$178.95 |
14% |
Griffin Securities |
Fibrocell Science Inc. (Exton, Pa.; FCSC) |
9/26/13 |
$4.10 |
$4.06 |
$50.43 |
-1% |
Griffin Securities |
Oragenics Inc. (Tampa, Fla.; OGEN) (lead) |
11/15/13 |
$2.50 |
$2.81 |
$11.00 |
12% |
Griffin Securities |
Ziopharm Oncology Inc. (Boston; ZIOP) |
10/24/13 |
$3.50 |
$4.34 |
$50.05 |
24% |
Guggenheim Securities |
Acelrx Pharmaceuticals Inc. (Redwood City, Calif.; ACRX) |
7/17/13 |
$11.65 |
$11.31 |
$50.90 |
-3% |
Guggenheim Securities |
Celldex Therapeutics Inc. (Hampton, N.J.; CLDX) |
12/5/13 |
$24.50 |
$24.21 |
$191.40 |
-1% |
Guggenheim Securities |
Five Prime Therapeutics Inc. (South San Francisco; FPRX) (IPO) |
9/18/13 |
$13.00 |
$16.79 |
$71.80 |
29% |
Guggenheim Securities |
Tetralogic Pharmaceuticals Inc. (Malvern, Pa.; TLOG) (co-lead) (IPO) |
12/12/13 |
$7.00 |
$9.52 |
$50.05 |
36% |
Guggenheim Securities |
Tetraphase Pharmaceuticals Inc. (Watertown, Mass; TTPH) |
11/4/13 |
$10.00 |
$13.52 |
$49.00 |
35% |
Guggenheim Securities |
Verastem Inc. (Cambridge, Mass.; VSTM) |
7/18/13 |
$15.00 |
$11.40 |
$64.50 |
-24% |
H.C. Wainwright & Co. |
Cytrx Corp. (Los Angeles; CYTR) |
10/10/13 |
$2.25 |
$6.27 |
$25.90 |
179% |
Janney Montgomery |
Cyclacel Pharmaceuticals Inc. (Berkeley Heights, N.J.; CYCC) |
5/16/13 |
$3.00 |
$4.02 |
$20.50 |
34% |
Janney Montgomery |
Durect Corp. (Cupertino, Calif.; DRRX) |
11/8/13 |
$1.40 |
$1.73 |
$11.50 |
24% |
Janney Montgomery |
Intercept Pharmaceuticals Inc. (New York; ICPT) |
6/19/13 |
$33.01 |
$68.28 |
$65.69 |
107% |
Janney Montgomery |
Onconova Therapeutics Inc. (Newtown, Pa.; ONTX) (IPO) |
7/25/13 |
$15.00 |
$11.48 |
$88.50 |
-23% |
Jefferies & Co. |
A.P. Pharma Inc. (Redwood City, Calif.; OTCBB:APPA) (co-lead) |
11/21/13 |
$0.40 |
$0.45 |
$60.00 |
13% |
Jefferies & Co. |
Acadia Pharmaceuticals Inc. (San Diego; ACAD) (co-lead) |
5/15/13 |
$12.50 |
$24.99 |
$115.00 |
100% |
Jefferies & Co. |
Acelrx Pharmaceuticals Inc. (Redwood City, Calif.; ACRX) (co-lead) |
7/17/13 |
$11.65 |
$11.31 |
$50.90 |
-3% |
Jefferies & Co. |
Aegerion Pharmaceuticals Inc. (Cambridge, Mass.; AEGR) (co-lead) |
1/14/13 |
$26.64 |
$70.96 |
$72.05 |
166% |
Jefferies & Co. |
Amarin Corp. plc (Dublin; AMRN) (co-lead) |
7/10/13 |
$5.60 |
$1.97 |
$121.52 |
-65% |
Jefferies & Co. |
Anthera Pharmaceuticals Inc.6 (Hayward, Calif.; ANTH) (lead) |
1/24/13 |
$5.28 |
$3.07 |
$40.00 |
-42% |
Jefferies & Co. |
Ariad Pharmaceuticals Inc. (Cambridge, Mass.; ARIA) (co-lead) |
1/24/13 |
$19.60 |
$6.82 |
$323.40 |
-65% |
Jefferies & Co. |
Celldex Therapeutics Inc. (Hampton, N.J.; CLDX) (co-lead) |
12/5/13 |
$24.50 |
$24.21 |
$191.40 |
-1% |
Jefferies & Co. |
Celldex Therapeutics Inc. (Needham, Mass.; CLDX) (co-lead) |
2/6/13 |
$7.50 |
$24.21 |
$103.50 |
223% |
Jefferies & Co. |
Durata Therapeutics Inc. (Chicago; DRTX) (co-lead) |
4/12/13 |
$7.00 |
$12.79 |
$50.05 |
83% |
Jefferies & Co. |
Dyax Corp. (Burlington, Mass.; DYAX) (lead) |
10/10/13 |
$6.50 |
$7.54 |
$60.00 |
16% |
Jefferies & Co. |
Five Prime Therapeutics Inc. (South San Francisco; FPRX) (co-lead) (IPO) |
9/18/13 |
$13.00 |
$16.79 |
$71.80 |
29% |
Jefferies & Co. |
Kamada Ltd. (Ness Ziona, Israel; KMDA) (co-lead) (IPO) |
5/31/13 |
$9.25 |
$14.87 |
$51.64 |
61% |
Jefferies & Co. |
Mirati Therapeutics Inc. (San Diego; MRTX) (co-lead) |
10/24/13 |
$17.50 |
$16.63 |
$56.90 |
-5% |
Jefferies & Co. |
Newlink Genetics Corp. (Ames, Iowa; NLNK) (lead) |
1/31/13 |
$11.40 |
$22.01 |
$52.44 |
93% |
Jefferies & Co. |
Oncomed Pharmaceuticals Inc. (Redwood City, Calif.; OMED) (co-lead) (IPO) |
7/18/13 |
$17.00 |
$29.52 |
$93.50 |
74% |
Jefferies & Co. |
Progenics Pharmaceuticals Inc. (Tarrytown, N.Y.; PGNX) (lead) |
6/21/13 |
$4.40 |
$5.33 |
$37.40 |
21% |
Jefferies & Co. |
Sagent Pharmaceuticals Inc. (Schaumburg, Ill.; SGNT) (co-lead) |
9/11/13 |
$21.25 |
$25.38 |
$75.28 |
19% |
Jefferies & Co. |
Synta Pharmaceuticals Corp. (Lexington, Mass.; SNTA) (lead) |
11/14/13 |
$3.75 |
$5.24 |
$60.38 |
40% |
Jefferies & Co. |
Verastem Inc. (Cambridge, Mass.; VSTM) (co-lead) |
7/18/13 |
$15.00 |
$11.40 |
$64.50 |
-24% |
Jefferies & Co. |
Xoma Corp. (Berkeley, Calif.; XOMA) (co-lead) |
12/13/13 |
$5.25 |
$6.73 |
$57.23 |
28% |
JMP Securities |
A.P. Pharma Inc. (Redwood City, Calif.; OTCBB:APPA) |
11/21/13 |
$0.40 |
$0.45 |
$60.00 |
13% |
JMP Securities |
Acadia Pharmaceuticals Inc. (San Diego; ACAD) |
5/15/13 |
$12.50 |
$24.99 |
$115.00 |
100% |
JMP Securities |
Acceleron Pharma Inc. (Cambridge, Mass.; XLRN) (IPO) |
9/19/13 |
$15.00 |
$39.60 |
$96.26 |
164% |
JMP Securities |
Achillion Pharmaceuticals Inc. (New Haven, Conn.; ACHN) |
3/1/13 |
$8.40 |
$3.32 |
$141.96 |
-60% |
JMP Securities |
Alcobra Ltd. (Tel Aviv, Israel; ADHD) (co-lead) |
10/25/13 |
$16.50 |
$18.00 |
$37.95 |
9% |
JMP Securities |
Alnylam Pharmaceuticals Inc. (Cambridge, Mass.; ALNY) |
1/16/13 |
$20.13 |
$64.30 |
$185.20 |
219% |
JMP Securities |
Axogen Inc. (Alachua, Fla.; AXGN) (lead) |
8/9/13 |
$3.00 |
$4.49 |
$18.60 |
50% |
JMP Securities |
Bind Therapeutics Inc. (Cambridge, Mass.; BIND) (IPO) |
9/20/13 |
$15.00 |
$15.09 |
$70.50 |
1% |
JMP Securities |
Biocryst Pharmaceuticals Inc. (Research Triangle Park, N.C.; BCRX) (co-lead) |
8/2/13 |
$4.40 |
$7.60 |
$20.20 |
73% |
JMP Securities |
Chelsea Therapeutics International Ltd. (Charlotte, N.C.; CHTP) (lead) |
11/14/13 |
$3.00 |
$4.43 |
$23.10 |
48% |
JMP Securities |
Conatus Pharmaceuticals Inc. (San Diego; CNAT) (IPO) |
7/25/13 |
$11.00 |
$6.45 |
$66.00 |
-41% |
JMP Securities |
Cyclacel Pharmaceuticals Inc. (Berkeley Heights, N.J.; CYCC) (lead) |
5/16/13 |
$3.00 |
$4.02 |
$20.50 |
34% |
JMP Securities |
Durata Therapeutics Inc. (Chicago; DRTX) |
4/12/13 |
$7.00 |
$12.79 |
$50.05 |
83% |
JMP Securities |
Enanta Pharmaceuticals Inc. (Watertown, Mass.; ENTA) (IPO) |
3/21/13 |
$14.00 |
$27.28 |
$64.40 |
95% |
JMP Securities |
Epizyme Inc. (Cambridge, Mass.; EPZM) (IPO) |
5/31/13 |
$15.00 |
$20.80 |
$88.70 |
39% |
JMP Securities |
Esperion Therapeutics Inc. (Plymouth, Mich.; ESPR) (IPO) |
6/26/13 |
$14.00 |
$13.74 |
$80.50 |
-2% |
JMP Securities |
Galena Biopharma Inc. (Portland, Ore.; GALE) |
9/13/13 |
$2.00 |
$4.96 |
$40.25 |
148% |
JMP Securities |
Hyperion Therapeutics Inc. (South San Francisco; HPTX) |
3/8/13 |
$20.75 |
$20.22 |
$67.00 |
-3% |
JMP Securities |
Insys Therapeutics Inc. (Phoenix; INSY) (co-lead) (IPO) |
5/2/13 |
$8.00 |
$38.71 |
$32.00 |
384% |
JMP Securities |
Intermune Inc. (Brisbane, Calif.; ITMN) |
11/6/13 |
$13.00 |
$14.73 |
$84.50 |
13% |
JMP Securities |
Kalobios Pharmaceuticals Inc. (South San Francisco; KBIO) |
9/26/13 |
$4.00 |
$4.42 |
$30.00 |
11% |
JMP Securities |
Karyopharm Therapeutics Inc. (Natick, Mass.; KPTI) (IPO) |
11/7/13 |
$16.00 |
$22.92 |
$125.12 |
43% |
JMP Securities |
Keryx Biopharmaceuticals Inc. (New York; KERX) |
1/31/13 |
$8.49 |
$12.95 |
$69.90 |
53% |
JMP Securities |
Organovo Holdings Inc. (San Diego; NYSE:ONVO) |
8/2/13 |
$4.50 |
$11.07 |
$46.58 |
146% |
JMP Securities |
Sangamo Biosciences Inc. (Richmond, Calif.; SGMO) (co-lead) |
9/19/13 |
$10.58 |
$13.89 |
$74.22 |
31% |
JMP Securities |
Synta Pharmaceuticals Corp. (Lexington, Mass.; SNTA) |
11/14/13 |
$3.75 |
$5.24 |
$60.38 |
40% |
JMP Securities |
Tetraphase Pharmaceuticals Inc. (Watertown, Mass.; TTPH) (IPO) |
3/20/13 |
$7.00 |
$13.52 |
$80.58 |
93% |
JMP Securities |
Tetraphase Pharmaceuticals Inc. (Watertown, Mass; TTPH) |
11/4/13 |
$10.00 |
$13.52 |
$49.00 |
35% |
JMP Securities |
Vanda Pharmaceuticals Inc. (Washington; VNDA) |
8/7/13 |
$11.14 |
$12.41 |
$52.14 |
11% |
JMP Securities |
Verastem Inc. (Cambridge, Mass.; VSTM) |
7/18/13 |
$15.00 |
$11.40 |
$64.50 |
-24% |
JMP Securities |
Ziopharm Oncology Inc. (Boston; ZIOP) |
10/24/13 |
$3.50 |
$4.34 |
$50.05 |
24% |
JP Morgan |
Aegerion Pharmaceuticals Inc. (Cambridge, Mass.; AEGR) (co-lead) |
1/14/13 |
$26.64 |
$70.96 |
$72.05 |
166% |
JP Morgan |
Agios Pharmaceuticals Inc. (Cambridge, Mass.; AGIO) (co-lead) (IPO) |
7/24/13 |
$18.00 |
$23.95 |
$120.60 |
33% |
JP Morgan |
Alnylam Pharmaceuticals Inc. (Cambridge, Mass.; ALNY) (co-lead) |
1/16/13 |
$20.13 |
$64.30 |
$185.20 |
219% |
JP Morgan |
Ariad Pharmaceuticals Inc. (Cambridge, Mass.; ARIA) (co-lead) |
1/24/13 |
$19.60 |
$6.82 |
$323.40 |
-65% |
JP Morgan |
Aveo Oncology Inc. (Cambridge, Mass.; AVEO) (lead) |
1/17/13 |
$7.50 |
$1.83 |
$57.75 |
-76% |
JP Morgan |
Bluebird Bio Inc. (Cambridge, Mass.; BLUE) (co-lead) (IPO) |
6/19/13 |
$17.00 |
$20.98 |
$116.11 |
23% |
JP Morgan |
Chemocentryx Inc. (Mountain View, Calif.; CCXI) (co-lead) |
4/17/13 |
$12.00 |
$5.79 |
$60.00 |
-52% |
JP Morgan |
Clovis Oncology Inc. (Boulder, Colo.; CLVS) (co-lead) |
6/12/13 |
$72.00 |
$60.27 |
$275.00 |
-16% |
JP Morgan |
Enanta Pharmaceuticals Inc. (Watertown, Mass.; ENTA) (co-lead) (IPO) |
3/21/13 |
$14.00 |
$27.28 |
$64.40 |
95% |
JP Morgan |
Intermune Inc. (Brisbane, Calif.; ITMN) (co-lead) |
1/16/13 |
$9.90 |
$14.73 |
$133.65 |
49% |
JP Morgan |
Intermune Inc. (Brisbane, Calif.; ITMN) (co-lead) |
11/6/13 |
$13.00 |
$14.73 |
$84.50 |
13% |
JP Morgan |
Ironwood Pharmaceuticals Inc. (Cambridge, Mass.; IRWD) (co-lead) |
5/22/13 |
$13.00 |
$11.61 |
$145.60 |
-11% |
JP Morgan |
Isis Pharmaceuticals Inc. (Carlsbad, Calif.; ISIS) (co-lead) |
5/9/13 |
$19.00 |
$39.84 |
$182.70 |
110% |
JP Morgan |
Keryx Biopharmaceuticals Inc. (New York; KERX) (lead) |
1/31/13 |
$8.49 |
$12.95 |
$69.90 |
53% |
JP Morgan |
Kythera Biopharmaceuticals Inc. (Calabasas, Calif.; KYTH) (co-lead) |
10/9/13 |
$45.75 |
$37.35 |
$120.00 |
-18% |
JP Morgan |
NPS Pharmaceuticals Inc. (Bedminster, N.J.; NPSP) (co-lead) |
5/20/13 |
$14.53 |
$30.36 |
$100.26 |
109% |
|
JP Morgan
|
Ophthotech Corp. (New York; OPHT) (co-lead) (IPO) |
9/25/13 |
$22.00 |
$32.35 |
$192.28 |
47% |
JP Morgan |
Pharmacyclics Inc. (Sunnyvale, Calif.; PCYC) (lead) |
3/8/13 |
$94.20 |
$105.78 |
$207.24 |
12% |
JP Morgan |
Prosensa Holding BV (Leiden, the Netherlands; RNA) (co-lead) (IPO) |
6/28/13 |
$13.00 |
$4.67 |
$89.70 |
-64% |
JP Morgan |
PTC Therapeutics Inc. (South Plainfield, N.J.; PTCT) (co-lead) (IPO) |
6/20/13 |
$15.00 |
$16.97 |
$144.48 |
13% |
JP Morgan |
Synageva Biopharma Corp. (Lexington, Mass.; GEVA) (co-lead) |
1/3/13 |
$47.53 |
$64.72 |
$118.83 |
36% |
JP Morgan |
Ziopharm Oncology Inc. (Boston; ZIOP) (lead) |
10/24/13 |
$3.50 |
$4.34 |
$50.05 |
24% |
KBC Securities |
Prosensa Holding BV (Leiden, the Netherlands; RNA) (IPO) |
6/28/13 |
$13.00 |
$4.67 |
$89.70 |
-64% |
Ladenburg Thalmann |
Acadia Pharmaceuticals Inc. (San Diego; ACAD) |
5/15/13 |
$12.50 |
$24.99 |
$115.00 |
100% |
Ladenburg Thalmann |
Adma Biologics Inc. (Hackensack, N.J.; OTCBB:ADMA) (IPO) |
10/17/13 |
$8.50 |
$7.80 |
$28.50 |
-8% |
Ladenburg Thalmann |
Axogen Inc. (Alachua, Fla.; AXGN) |
8/9/13 |
$3.00 |
$4.49 |
$18.60 |
50% |
Ladenburg Thalmann |
Biodel Inc. (Danbury, Conn.; BIOD) |
6/20/13 |
$4.35 |
$2.28 |
$19.49 |
-48% |
Ladenburg Thalmann |
Chelsea Therapeutics International Ltd. (Charlotte, N.C.; CHTP) |
11/14/13 |
$3.00 |
$4.43 |
$23.10 |
48% |
Ladenburg Thalmann |
Ironwood Pharmaceuticals Inc. (Cambridge, Mass.; IRWD) |
5/22/13 |
$13.00 |
$11.61 |
$145.60 |
-11% |
Ladenburg Thalmann |
Keryx Biopharmaceuticals Inc. (New York; KERX) |
1/31/13 |
$8.49 |
$12.95 |
$69.90 |
53% |
Ladenburg Thalmann |
Lipocine Inc. (Salt Lake City; OCTQB:LPCN) (lead) |
11/27/13 |
$8.25 |
$8.25 |
$12.30 |
0% |
Ladenburg Thalmann |
Navidea Biopharmaceuticals Inc. (Dublin, Ohio; NAVB) (lead) |
1/31/13 |
$3.10 |
$2.07 |
$4.78 |
-33% |
Ladenburg Thalmann |
Oxygen Biotherapeutics Inc.1 (Morrisville, N.C.; OXBT) (lead) |
7/22/13 |
$1.95 |
$4.50 |
$5.40 |
131% |
Ladenburg Thalmann |
Psivida Corp. (Watertown, Mass.; PSDV) (lead) |
7/18/13 |
$3.10 |
$3.97 |
$10.80 |
28% |
Ladenburg Thalmann |
Repros Therapeutics Inc. (The Woodlands, Texas; RPRX) |
6/20/13 |
$19.00 |
$18.30 |
$81.94 |
-4% |
Ladenburg Thalmann |
TG Therapeutics Inc. (New York; TGTX) (co-lead) |
7/18/13 |
$6.15 |
$3.90 |
$35.10 |
-37% |
Laidlaw & Co. |
Adma Biologics Inc. (Hackensack, N.J.; OTCBB:ADMA) (IPO) |
10/17/13 |
$8.50 |
$7.80 |
$28.50 |
-8% |
Laidlaw & Co. |
Cel-Sci Corp. (Vienna, Va.; NYSE Amex:CVM) (co-lead) |
10/9/13 |
$1.00 |
$0.59 |
$17.80 |
-41% |
Laidlaw & Co. |
Cel-Sci Corp. (Vienna, Va.; NYSE:CVM) (co-lead) |
12/20/13 |
$0.63 |
$0.59 |
$3.30 |
-6% |
Lake Street Capital Markets |
Mimedx Group Inc. (Marietta, Ga.; MDXG) |
12/12/13 |
$6.80 |
$8.74 |
$34.00 |
29% |
Lazard Capital |
Apricus Biosciences Inc. (San Diego; APRI) (lead) |
5/24/13 |
$2.85 |
$2.65 |
$17.10 |
-7% |
Lazard Capital |
Chimerix Inc. (Research Triangle Park, N.C.; CMRX) (IPO) |
4/11/13 |
$14.00 |
$15.11 |
$102.50 |
8% |
Lazard Capital |
Discovery Laboratories Inc. (Warrington, Pa.; DSCO) |
11/1/13 |
$2.00 |
$2.25 |
$50.00 |
13% |
Lazard Capital |
GW Pharma plc (Wilshire, UK; GWPH) (co-lead) (IPO) |
5/1/13 |
$8.90 |
$41.54 |
$31.15 |
367% |
Lazard Capital |
Insmed Inc. (Monmouth Junction, N.J.; INSM) |
7/17/13 |
$10.40 |
$17.00 |
$62.40 |
63% |
Lazard Capital |
Macrogenics Inc. (Rockville, Md.; MGNX) (IPO) |
10/11/13 |
$16.00 |
$27.43 |
$92.00 |
71% |
Lazard Capital |
Novavax Inc. (Rockville, Md.; NVAX) (lead) |
9/24/13 |
$3.14 |
$5.12 |
$99.85 |
63% |
Lazard Capital |
Organovo Holdings Inc. (San Diego; NYSE:ONVO) (co-lead) |
8/2/13 |
$4.50 |
$11.07 |
$46.58 |
146% |
Lazard Capital |
Regulus Therapeutics Inc. (La Jolla, Calif.; RGLS) (co-lead) |
7/17/13 |
$9.50 |
$7.39 |
$49.20 |
-22% |
Lazard Capital |
Repros Therapeutics Inc. (The Woodlands, Texas; RPRX) |
6/20/13 |
$19.00 |
$18.30 |
$81.94 |
-4% |
Lazard Capital |
Sangamo Biosciences Inc. (Richmond, Calif.; SGMO) (co-lead) |
9/19/13 |
$10.58 |
$13.89 |
$74.22 |
31% |
Lazard Capital |
Sophiris Bio Inc. (San Diego; SPHS) (IPO) |
8/16/13 |
$5.00 |
$3.70 |
$65.00 |
-26% |
Lazard Capital |
Vanda Pharmaceuticals Inc. (Washington; VNDA) (co-lead) |
8/7/13 |
$11.14 |
$12.41 |
$52.14 |
11% |
Lazard Capital |
Verastem Inc. (Cambridge, Mass.; VSTM) |
7/18/13 |
$15.00 |
$11.40 |
$64.50 |
-24% |
Lazard Capital |
Cerus Corp. (Concord, Calif.; CERS) |
3/14/13 |
$4.20 |
$6.45 |
$35.00 |
54% |
Leerink Swann |
A.P. Pharma Inc. (Redwood City, Calif.; OTCBB:APPA) (co-lead) |
11/21/13 |
$0.40 |
$0.45 |
$60.00 |
13% |
Leerink Swann |
Acceleron Pharma Inc. (Cambridge, Mass.; XLRN) (co-lead) (IPO) |
9/19/13 |
$15.00 |
$39.60 |
$96.26 |
164% |
Leerink Swann |
Achillion Pharmaceuticals Inc. (New Haven, Conn.; ACHN) (co-lead) |
3/1/13 |
$8.40 |
$3.32 |
$141.96 |
-60% |
Leerink Swann |
Aegerion Pharmaceuticals Inc. (Cambridge, Mass.; AEGR) |
1/14/13 |
$26.64 |
$70.96 |
$72.05 |
166% |
Leerink Swann |
Agios Pharmaceuticals Inc. (Cambridge, Mass.; AGIO) (IPO) |
7/24/13 |
$18.00 |
$23.95 |
$120.60 |
33% |
Leerink Swann |
Alnylam Pharmaceuticals Inc. (Cambridge, Mass.; ALNY) |
1/16/13 |
$20.13 |
$64.30 |
$185.20 |
219% |
Leerink Swann |
Ambit Biosciences Inc. (San Diego; AMBI) (co-lead) (IPO) |
5/16/13 |
$8.00 |
$9.64 |
$65.00 |
21% |
Leerink Swann |
Anthera Pharmaceuticals Inc.6 (Hayward, Calif.; ANTH) |
1/24/13 |
$5.28 |
$3.07 |
$40.00 |
-42% |
Leerink Swann |
Ariad Pharmaceuticals Inc. (Cambridge, Mass.; ARIA) |
1/24/13 |
$19.60 |
$6.82 |
$323.40 |
-65% |
Leerink Swann |
Celldex Therapeutics Inc. (Needham, Mass.; CLDX) (co-lead) |
2/6/13 |
$7.50 |
$24.21 |
$103.50 |
223% |
Leerink Swann |
Clovis Oncology Inc. (Boulder, Colo.; CLVS) |
6/12/13 |
$72.00 |
$60.27 |
$275.00 |
-16% |
Leerink Swann |
Dyax Corp. (Burlington, Mass.; DYAX) |
10/10/13 |
$6.50 |
$7.54 |
$60.00 |
16% |
Leerink Swann |
Intermune Inc. (Brisbane, Calif.; ITMN) |
11/6/13 |
$13.00 |
$14.73 |
$84.50 |
13% |
Leerink Swann |
Kalobios Pharmaceuticals Inc. (South San Francisco; KBIO) (lead) |
9/26/13 |
$4.00 |
$4.42 |
$30.00 |
11% |
Leerink Swann |
Karyopharm Therapeutics Inc. (Natick, Mass.; KPTI) (co-lead) (IPO) |
11/7/13 |
$16.00 |
$22.92 |
$125.12 |
43% |
Leerink Swann |
Kythera Biopharmaceuticals Inc. (Calabasas, Calif.; KYTH) (co-lead) |
10/9/13 |
$45.75 |
$37.35 |
$120.00 |
-18% |
Leerink Swann |
Macrogenics Inc. (Rockville, Md.; MGNX) (co-lead) (IPO) |
10/11/13 |
$16.00 |
$27.43 |
$92.00 |
71% |
Leerink Swann |
Mirati Therapeutics Inc. (San Diego; MRTX) (co-lead) |
10/24/13 |
$17.50 |
$16.63 |
$56.90 |
-5% |
Leerink Swann |
Ophthotech Corp. (New York; OPHT) (IPO) |
9/25/13 |
$22.00 |
$32.35 |
$192.28 |
47% |
Leerink Swann |
Sophiris Bio Inc. (San Diego; SPHS) (co-lead) (IPO) |
8/16/13 |
$5.00 |
$3.70 |
$65.00 |
-26% |
Leerink Swann |
Zogenix Inc. (San Diego; ZGNX) (co-lead) |
11/4/13 |
$2.25 |
$3.44 |
$68.85 |
53% |
Leerink Swann |
Celldex Therapeutics Inc. (Hampton, N.J.; CLDX) (co-lead) |
12/5/13 |
$24.50 |
$24.21 |
$191.40 |
-1% |
Leerink Swann |
Enanta Pharmaceuticals Inc. (Watertown, Mass.; ENTA) (IPO) |
3/21/13 |
$14.00 |
$27.28 |
$64.40 |
95% |
Leerink Swann |
Epizyme Inc. (Cambridge, Mass.; EPZM) (co-lead) (IPO) |
5/31/13 |
$15.00 |
$20.80 |
$88.70 |
39% |
Leerink Swann |
Hyperion Therapeutics Inc. (South San Francisco; HPTX) (co-lead) |
3/8/13 |
$20.75 |
$20.22 |
$67.00 |
-3% |
Leerink Swann |
Insmed Inc. (Monmouth Junction, N.J.; INSM) (lead) |
7/17/13 |
$10.40 |
$17.00 |
$62.40 |
63% |
Leerink Swann |
Intermune Inc. (Brisbane, Calif.; ITMN) |
1/16/13 |
$9.90 |
$14.73 |
$133.65 |
49% |
Leerink Swann |
Kalobios Pharmaceuticals Inc. (South San Francisco; KBIO) (lead) (IPO) |
1/31/13 |
$8.00 |
$4.42 |
$70.00 |
-45% |
Leerink Swann |
NPS Pharmaceuticals Inc. (Bedminster, N.J.; NPSP) |
5/20/13 |
$14.53 |
$30.36 |
$100.26 |
109% |
Leerink Swann |
Omthera Pharmaceuticals Inc.2 (Princeton, N.J.; OMTH) (co-lead) (IPO) |
4/12/13 |
$8.00 |
$12.70 |
$64.00 |
59% |
Leerink Swann |
Oncomed Pharmaceuticals Inc. (Redwood City, Calif.; OMED) (co-lead) (IPO) |
7/18/13 |
$17.00 |
$29.52 |
$93.50 |
74% |
Leerink Swann |
Onconova Therapeutics Inc. (Newtown, Pa.; ONTX) (co-lead) (IPO) |
7/25/13 |
$15.00 |
$11.48 |
$88.50 |
-23% |
Leerink Swann |
Prosensa Holding BV (Leiden, the Netherlands; RNA) (co-lead) (IPO) |
6/28/13 |
$13.00 |
$4.67 |
$89.70 |
-64% |
Leerink Swann |
Receptos Inc. (San Diego; RCPT) (co-lead) (IPO) |
5/9/13 |
$14.00 |
$28.99 |
$72.80 |
107% |
Leerink Swann |
Synageva Biopharma Corp. (Lexington, Mass.; GEVA) |
1/3/13 |
$47.53 |
$64.72 |
$118.83 |
36% |
Leerink Swann |
Tesaro Inc. (Waltham, Mass.; TSRO) |
3/1/13 |
$18.00 |
$28.24 |
$97.20 |
57% |
Leerink Swann |
Trius Therapeutics Inc.7 (San Diego; TSRX) (co-lead) |
1/18/13 |
$4.75 |
$13.63 |
$34.20 |
187% |
Leerink Swann |
Verastem Inc. (Cambridge, Mass.; VSTM) (co-lead) |
7/18/13 |
$15.00 |
$11.40 |
$64.50 |
-24% |
Leerink Swann |
Xencor Inc. (Redwood City, Calif.; XNCR) (co-lead) (IPO) |
12/3/13 |
$5.50 |
$9.14 |
$80.30 |
66% |
Maxim Group LLC |
Aastrom Biosciences Inc.3 (Ann Arbor, Mich.; ASTM) (co-lead) |
8/14/13 |
$6.00 |
$3.23 |
$8.70 |
-46% |
Maxim Group LLC |
Adma Biologics Inc. (Hackensack, N.J.; OTCBB:ADMA) (IPO) |
10/17/13 |
$8.50 |
$7.80 |
$28.50 |
-8% |
Maxim Group LLC |
Aeterna Zentaris Inc. (Quebec City; AEZS) |
11/20/13 |
$1.15 |
$1.38 |
$15.00 |
20% |
Maxim Group LLC |
Brainstorm Cell Therapeutics Inc. (New York; OTCQB:BCLI) (co-lead) |
8/13/13 |
$0.17 |
$0.18 |
$4.00 |
6% |
Maxim Group LLC |
Galena Biopharma Inc. (Portland, Ore.; GALE) |
9/13/13 |
$2.00 |
$4.96 |
$40.25 |
148% |
Maxim Group LLC |
Inovio Pharmaceuticals Inc. (Blue Bell, Pa.; NYSE:INO) |
3/7/13 |
$0.55 |
$2.90 |
$15.06 |
427% |
Maxim Group LLC |
Intellipharmaceutics International Inc. (Toronto; IPCI) (lead) |
8/1/13 |
$2.05 |
$3.71 |
$3.10 |
81% |
Maxim Group LLC |
Medgenics Inc. (San Francisco; MDGN) (lead) |
3/26/13 |
$5.25 |
$5.99 |
$31.87 |
14% |
Maxim Group LLC |
Organovo Holdings Inc. (San Diego; NYSE:ONVO) |
8/2/13 |
$4.50 |
$11.07 |
$46.58 |
146% |
Maxim Group LLC |
Stemcells Inc. (Newark, Calif.; STEM) (co-lead) |
10/2/13 |
$1.45 |
$1.23 |
$18.63 |
-15% |
Maxim Group LLC |
Tekmira Pharmaceuticals Corp. (Vancouver, British Columbia; TKMR) |
10/18/13 |
$8.00 |
$7.97 |
$35.00 |
0% |
MDB Capital Group |
Imprimis Pharmaceuticals Inc. (Solana Beach, Calif.; IMMY) (co-lead) |
2/11/13 |
$5.25 |
$3.36 |
$9.66 |
-36% |
Mizuho Securities |
Ironwood Pharmaceuticals Inc. (Cambridge, Mass.; IRWD) |
5/22/13 |
$13.00 |
$11.61 |
$145.60 |
-11% |
MLV & Co. |
Galena Biopharma Inc. (Portland, Ore.; GALE) |
9/13/13 |
$2.00 |
$4.96 |
$40.25 |
148% |
MLV & Co. |
Medgenics Inc. (San Francisco; MDGN) |
3/26/13 |
$5.25 |
$5.99 |
$31.87 |
14% |
MLV & Co. |
Psivida Corp. (Watertown, Mass.; PSDV) |
7/18/13 |
$3.10 |
$3.97 |
$10.80 |
28% |
Morgan Stanley |
Alnylam Pharmaceuticals Inc. (Cambridge, Mass.; ALNY) (co-lead) |
1/16/13 |
$20.13 |
$64.30 |
$185.20 |
219% |
Morgan Stanley |
Chimerix Inc. (Research Triangle Park, N.C.; CMRX) (co-lead) (IPO) |
4/11/13 |
$14.00 |
$15.11 |
$102.50 |
8% |
Morgan Stanley |
Ironwood Pharmaceuticals Inc. (Cambridge, Mass.; IRWD) (co-lead) |
5/22/13 |
$13.00 |
$11.61 |
$145.60 |
-11% |
Morgan Stanley |
Kamada Ltd. (Ness Ziona, Israel; KMDA) (co-lead) (IPO) |
5/31/13 |
$9.25 |
$14.87 |
$51.64 |
61% |
Morgan Stanley |
NPS Pharmaceuticals Inc. (Bedminster, N.J.; NPSP) (co-lead) |
5/20/13 |
$14.53 |
$30.36 |
$100.26 |
109% |
Morgan Stanley |
Ophthotech Corp. (New York; OPHT) (co-lead) (IPO) |
9/25/13 |
$22.00 |
$32.35 |
$192.28 |
47% |
Morgan Stanley |
Portola Pharmaceuticals Inc. (South San Francisco; PTLA) (co-lead) |
10/17/13 |
$23.75 |
$25.75 |
$105.90 |
8% |
Morgan Stanley |
Portola Pharmaceuticals Inc. (South San Francisco; PTLA) (co-lead) (IPO) |
5/22/13 |
$14.50 |
$25.75 |
$122.10 |
78% |
Morgan Stanley |
Relypsa Inc. (Redwood City, Calif.; RLYP) (co-lead) (IPO) |
11/15/13 |
$11.00 |
$25.00 |
$85.80 |
127% |
Morgan Stanley |
Sagent Pharmaceuticals Inc. (Schaumburg, Ill.; SGNT) (co-lead) |
9/11/13 |
$21.25 |
$25.38 |
$75.28 |
19% |
Morgan Stanley |
Synageva Biopharma Corp. (Lexington, Mass.; GEVA) |
9/25/13 |
$56.63 |
$64.72 |
$178.95 |
14% |
Morgan Stanley |
Synageva Biopharma Corp. (Lexington, Mass.; GEVA) (co-lead) |
1/3/13 |
$47.53 |
$64.72 |
$118.83 |
36% |
Morgan Stanley |
Tesaro Inc. (Waltham, Mass.; TSRO) (co-lead) |
3/1/13 |
$18.00 |
$28.24 |
$97.20 |
57% |
National Securities Corp. |
Lipocine Inc. (Salt Lake City; OCTQB:LPCN) |
11/27/13 |
$8.25 |
$8.25 |
$12.30 |
0% |
National Securities Corp. |
Medgenics Inc. (San Francisco; MDGN) |
3/26/13 |
$5.25 |
$5.99 |
$31.87 |
14% |
National Securities Corp. |
TG Therapeutics Inc. (New York; TGTX) |
7/18/13 |
$6.15 |
$3.90 |
$35.10 |
-37% |
National Securities Corp. |
Tonix Pharmaceuticals Holding Corp. (New York; TNXP) |
8/9/13 |
$4.25 |
$10.31 |
$11.39 |
143% |
Needham & Co. |
Acadia Pharmaceuticals Inc. (San Diego; ACAD) |
5/15/13 |
$12.50 |
$24.99 |
$115.00 |
100% |
Needham & Co. |
Aerie Pharmaceuticals Inc. (Bedminster, N.J.; AERI) (IPO) |
10/28/13 |
$10.00 |
$17.96 |
$77.20 |
80% |
Needham & Co. |
Alnylam Pharmaceuticals Inc. (Cambridge, Mass.; ALNY) |
1/16/13 |
$20.13 |
$64.30 |
$185.20 |
219% |
Needham & Co. |
Cempra Inc. (Chapel Hill, N.C.; CEMP) |
6/14/13 |
$7.00 |
$12.39 |
$57.75 |
77% |
Needham & Co. |
Chelsea Therapeutics International Ltd. (Charlotte, N.C.; CHTP) |
11/14/13 |
$3.00 |
$4.43 |
$23.10 |
48% |
Needham & Co. |
Dyax Corp. (Burlington, Mass.; DYAX) |
10/10/13 |
$6.50 |
$7.54 |
$60.00 |
16% |
Needham & Co. |
Hyperion Therapeutics Inc. (South San Francisco; HPTX) |
3/8/13 |
$20.75 |
$20.22 |
$67.00 |
-3% |
Needham & Co. |
Intercept Pharmaceuticals Inc. (New York; ICPT) |
6/19/13 |
$33.01 |
$68.28 |
$65.69 |
107% |
Needham & Co. |
Isis Pharmaceuticals Inc. (Carlsbad, Calif.; ISIS) |
5/9/13 |
$19.00 |
$39.84 |
$182.70 |
110% |
Needham & Co. |
Kalobios Pharmaceuticals Inc. (South San Francisco; KBIO) |
9/26/13 |
$4.00 |
$4.42 |
$30.00 |
11% |
Needham & Co. |
Kalobios Pharmaceuticals Inc. (South San Francisco; KBIO) (IPO) |
1/31/13 |
$8.00 |
$4.42 |
$70.00 |
-45% |
Needham & Co. |
Progenics Pharmaceuticals Inc. (Tarrytown, N.Y.; PGNX) |
6/21/13 |
$4.40 |
$5.33 |
$37.40 |
21% |
Needham & Co. |
Regado Biosciences Inc. (Basking Ridge, N.J.; RGDO) (IPO) |
8/22/13 |
$4.00 |
$4.77 |
$46.68 |
19% |
Needham & Co. |
Sagent Pharmaceuticals Inc. (Schaumburg, Ill.; SGNT) |
9/11/13 |
$21.25 |
$25.38 |
$75.28 |
19% |
Needham & Co. |
Tetraphase Pharmaceuticals Inc. (Watertown, Mass; TTPH) |
11/4/13 |
$10.00 |
$13.52 |
$49.00 |
35% |
Needham & Co. |
Regulus Therapeutics Inc. (La Jolla, Calif.; RGLS) |
7/17/13 |
$9.50 |
$7.39 |
$49.20 |
-22% |
Needham & Co. |
Tetralogic Pharmaceuticals Inc. (Malvern, Pa.; TLOG) (co-lead) (IPO) |
12/12/13 |
$7.00 |
$9.52 |
$50.05 |
36% |
Needham & Co. |
Tetraphase Pharmaceuticals Inc. (Watertown, Mass.; TTPH) (IPO) |
3/20/13 |
$7.00 |
$13.52 |
$80.58 |
93% |
Newport Coast Securities |
Adamis Pharmaceuticals Corp. (San Diego; ADMP) |
12/16/13 |
$5.95 |
$6.39 |
$22.00 |
7% |
Noble Financial Capital |
Biocryst Pharmaceuticals Inc. (Research Triangle Park, N.C.; BCRX) |
8/2/13 |
$4.40 |
$7.60 |
$20.20 |
73% |
Noble Financial Capital |
Galena Biopharma Inc. (Portland, Ore.; GALE) |
9/13/13 |
$2.00 |
$4.96 |
$40.25 |
148% |
Northland Capital |
Mimedx Group Inc. (Marietta, Ga.; MDXG) |
12/12/13 |
$6.80 |
$8.74 |
$34.00 |
29% |
Oppenheimer & Co. |
A.P. Pharma Inc. (Redwood City, Calif.; OTCBB:APPA) |
11/21/13 |
$0.40 |
$0.45 |
$60.00 |
13% |
Oppenheimer & Co. |
Adma Biologics Inc. (Hackensack, N.J.; OTCBB:ADMA) (lead) (IPO) |
10/17/13 |
$8.50 |
$7.80 |
$28.50 |
-8% |
Oppenheimer & Co. |
Celldex Therapeutics Inc. (Hampton, N.J.; CLDX) |
12/5/13 |
$24.50 |
$24.21 |
$191.40 |
-1% |
Oppenheimer & Co. |
Celldex Therapeutics Inc. (Needham, Mass.; CLDX) |
2/6/13 |
$7.50 |
$24.21 |
$103.50 |
223% |
Oppenheimer & Co. |
Galena Biopharma Inc. (Portland, Ore.; GALE) (lead) |
9/13/13 |
$2.00 |
$4.96 |
$40.25 |
148% |
Oppenheimer & Co. |
Immunomedics Inc. (Morris Plains, N.J.; IMMU) (co-lead) |
2/22/13 |
$2.30 |
$4.60 |
$14.00 |
100% |
Oppenheimer & Co. |
Insys Therapeutics Inc. (Phoenix; INSY) (IPO) |
5/2/13 |
$8.00 |
$38.71 |
$32.00 |
384% |
Oppenheimer & Co. |
Kamada Ltd. (Ness Ziona, Israel; KMDA) (IPO) |
5/31/13 |
$9.25 |
$14.87 |
$51.64 |
61% |
Oppenheimer & Co. |
Karyopharm Therapeutics Inc. (Natick, Mass.; KPTI) (IPO) |
11/7/13 |
$16.00 |
$22.92 |
$125.12 |
43% |
Oppenheimer & Co. |
Keryx Biopharmaceuticals Inc. (New York; KERX) |
1/31/13 |
$8.49 |
$12.95 |
$69.90 |
53% |
Oppenheimer & Co. |
Northwest Biotherapeutics Inc. (Bethesda, Md.; NWBO) (lead) |
11/21/13 |
$4.80 |
$3.77 |
$23.50 |
-21% |
Oppenheimer & Co. |
Organovo Holdings Inc. (San Diego; NYSE:ONVO) (co-lead) |
8/2/13 |
$4.50 |
$11.07 |
$46.58 |
146% |
Oppenheimer & Co. |
Tetralogic Pharmaceuticals Inc. (Malvern, Pa.; TLOG) (co-lead) (IPO) |
12/12/13 |
$7.00 |
$9.52 |
$50.05 |
36% |
Oppenheimer & Co. |
Verastem Inc. (Cambridge, Mass.; VSTM) |
7/18/13 |
$15.00 |
$11.40 |
$64.50 |
-24% |
Oppenheimer & Co. |
Zogenix Inc. (San Diego; ZGNX) |
11/4/13 |
$2.25 |
$3.44 |
$68.85 |
53% |
Paradigm Capital |
Oncolytics Biotech Inc. (Calgary, Alberta; ONCY) |
2/21/13 |
$4.00 |
$1.55 |
$32.00 |
-61% |
Piper Jaffray & Co. |
Acceleron Pharma Inc. (Cambridge, Mass.; XLRN) (IPO) |
9/19/13 |
$15.00 |
$39.60 |
$96.26 |
164% |
Piper Jaffray & Co. |
Acelrx Pharmaceuticals Inc. (Redwood City, Calif.; ACRX) (co-lead) |
7/17/13 |
$11.65 |
$11.31 |
$50.90 |
-3% |
Piper Jaffray & Co. |
Achillion Pharmaceuticals Inc. (New Haven, Conn.; ACHN) |
3/1/13 |
$8.40 |
$3.32 |
$141.96 |
-60% |
Piper Jaffray & Co. |
Alnylam Pharmaceuticals Inc. (Cambridge, Mass.; ALNY) |
1/16/13 |
$20.13 |
$64.30 |
$185.20 |
219% |
Piper Jaffray & Co. |
Conatus Pharmaceuticals Inc. (San Diego; CNAT) (co-lead) (IPO) |
7/25/13 |
$11.00 |
$6.45 |
$66.00 |
-41% |
Piper Jaffray & Co. |
Discovery Laboratories Inc. (Warrington, Pa.; DSCO) (co-lead) |
11/1/13 |
$2.00 |
$2.25 |
$50.00 |
13% |
Piper Jaffray & Co. |
Idera Pharmaceuticals Inc. (Cambridge, Mass.; IDRA) (lead) |
9/26/13 |
$1.55 |
$4.63 |
$27.70 |
199% |
Piper Jaffray & Co. |
Idera Pharmaceuticals Inc. (Cambridge, Mass.; IDRA) (lead) |
5/2/13 |
$0.50 |
$4.63 |
$16.50 |
826% |
Piper Jaffray & Co. |
Mast Therapeutics Inc. (San Diego; MSTX) (co-lead) |
6/14/13 |
$0.50 |
$0.46 |
$25.00 |
-8% |
Piper Jaffray & Co. |
Mirati Therapeutics Inc. (San Diego; MRTX) |
10/24/13 |
$17.50 |
$16.63 |
$56.90 |
-5% |
Piper Jaffray & Co. |
Novavax Inc. (Rockville, Md.; NVAX) |
9/24/13 |
$3.14 |
$5.12 |
$99.85 |
63% |
Piper Jaffray & Co. |
Omthera Pharmaceuticals Inc.2 (Princeton, N.J.; OMTH) (IPO) |
4/12/13 |
$8.00 |
$12.70 |
$64.00 |
59% |
Piper Jaffray & Co. |
Oncolytics Biotech Inc. (Calgary, Alberta; ONCY) (co-lead) |
2/21/13 |
$4.00 |
$1.55 |
$32.00 |
-61% |
Piper Jaffray & Co. |
Oncomed Pharmaceuticals Inc. (Redwood City, Calif.; OMED) (IPO) |
7/18/13 |
$17.00 |
$29.52 |
$93.50 |
74% |
Piper Jaffray & Co. |
Onconova Therapeutics Inc. (Newtown, Pa.; ONTX) (IPO) |
7/25/13 |
$15.00 |
$11.48 |
$88.50 |
-23% |
Piper Jaffray & Co. |
Sagent Pharmaceuticals Inc. (Schaumburg, Ill.; SGNT) |
9/11/13 |
$21.25 |
$25.38 |
$75.28 |
19% |
Piper Jaffray & Co. |
Sangamo Biosciences Inc. (Richmond, Calif.; SGMO) (co-lead) |
9/19/13 |
$10.58 |
$13.89 |
$74.22 |
31% |
Piper Jaffray & Co. |
Vanda Pharmaceuticals Inc. (Washington; VNDA) (co-lead) |
8/7/13 |
$11.14 |
$12.41 |
$52.14 |
11% |
Piper Jaffray & Co. |
Xoma Corp. (Berkeley, Calif.; XOMA) |
12/13/13 |
$5.25 |
$6.73 |
$57.23 |
28% |
RBC Capital Markets |
Aerie Pharmaceuticals Inc. (Bedminster, N.J.; AERI) (IPO) (co-lead) |
10/28/13 |
$10.00 |
$17.96 |
$77.20 |
80% |
RBC Capital Markets |
Ariad Pharmaceuticals Inc. (Cambridge, Mass.; ARIA) |
1/24/13 |
$19.60 |
$6.82 |
$323.40 |
-65% |
RBC Capital Markets |
Aveo Oncology Inc. (Cambridge, Mass.; AVEO) |
1/17/13 |
$7.50 |
$1.83 |
$57.75 |
-76% |
RBC Capital Markets |
Durata Therapeutics Inc. (Chicago; DRTX) |
4/12/13 |
$7.00 |
$12.79 |
$50.05 |
83% |
RBC Capital Markets |
Kamada Ltd. (Ness Ziona, Israel; KMDA) (IPO) |
5/31/13 |
$9.25 |
$14.87 |
$51.64 |
61% |
RBC Capital Markets |
Prothena Corp. plc (Dublin; PRTA) (co-lead) |
10/13/13 |
$22.00 |
$26.52 |
$77.00 |
21% |
RBC Capital Markets |
Xoma Corp. (Berkeley, Calif.; XOMA) |
12/13/13 |
$5.25 |
$6.73 |
$57.23 |
28% |
Roth Capital Partners |
Acadia Pharmaceuticals Inc. (San Diego; ACAD) |
5/15/13 |
$12.50 |
$24.99 |
$115.00 |
100% |
Roth Capital Partners |
Apricus Biosciences Inc. (San Diego; APRI) |
5/24/13 |
$2.85 |
$2.65 |
$17.10 |
-7% |
Roth Capital Partners |
Brainstorm Cell Therapeutics Inc. (New York; OTCQB:BCLI) (co-lead) |
8/13/13 |
$0.17 |
$0.18 |
$4.00 |
6% |
Roth Capital Partners |
Celldex Therapeutics Inc. (Hampton, N.J.; CLDX) |
12/5/13 |
$24.50 |
$24.21 |
$191.40 |
-1% |
Roth Capital Partners |
Celldex Therapeutics Inc. (Needham, Mass.; CLDX) |
2/6/13 |
$7.50 |
$24.21 |
$103.50 |
223% |
Roth Capital Partners |
Delcath Systems Inc. (New York; DCTH) (lead) |
10/23/13 |
$0.36 |
$0.26 |
$7.55 |
-28% |
Roth Capital Partners |
Discovery Laboratories Inc. (Warrington, Pa.; DSCO) |
11/1/13 |
$2.00 |
$2.25 |
$50.00 |
13% |
Roth Capital Partners |
Galena Biopharma Inc. (Portland, Ore.; GALE) |
9/13/13 |
$2.00 |
$4.96 |
$40.25 |
148% |
Roth Capital Partners |
GW Pharma plc (Wilshire, UK; GWPH) (IPO) |
5/1/13 |
$8.90 |
$41.54 |
$31.15 |
367% |
Roth Capital Partners |
iBio Inc. (Newark, Del.; IBIO) (lead) |
4/23/13 |
$0.48 |
$0.34 |
$4.28 |
-29% |
Roth Capital Partners |
International Stem Cell Corp. (Carlsbad, Calif.; ISCO) (lead) |
7/19/13 |
$0.15 |
$0.21 |
$3.00 |
40% |
Roth Capital Partners |
Keryx Biopharmaceuticals Inc. (New York; KERX) |
1/31/13 |
$8.49 |
$12.95 |
$69.90 |
53% |
Roth Capital Partners |
Mei Pharma Inc. (San Diego; MEIP) |
10/28/13 |
$8.00 |
$8.01 |
$35.00 |
0% |
Roth Capital Partners |
Mei Pharma Inc. (San Diego; MEIP) |
4/5/13 |
$7.50 |
$8.01 |
$15.20 |
7% |
Roth Capital Partners |
Prothena Corp. plc (Dublin; PRTA) |
10/13/13 |
$22.00 |
$26.52 |
$77.00 |
21% |
Roth Capital Partners |
Stemline Therapeutics Inc. (New York; STML) (lead) |
5/17/13 |
$14.50 |
$19.60 |
$69.00 |
35% |
Roth Capital Partners |
Synta Pharmaceuticals Corp. (Lexington, Mass.; SNTA) |
11/14/13 |
$3.75 |
$5.24 |
$60.38 |
40% |
Roth Capital Partners |
TG Therapeutics Inc. (New York; TGTX) (co-lead) |
7/18/13 |
$6.15 |
$3.90 |
$35.10 |
-37% |
Roth Capital Partners |
Tonix Pharmaceuticals Holding Corp. (New York; TNXP) (lead) |
8/9/13 |
$4.25 |
$10.31 |
$11.39 |
143% |
Roth Capital Partners |
Verastem Inc. (Cambridge, Mass.; VSTM) |
7/18/13 |
$15.00 |
$11.40 |
$64.50 |
-24% |
Roth Capital Partners |
Xoma Corp. (Berkeley, Calif.; XOMA) |
8/20/13 |
$3.62 |
$6.73 |
$31.50 |
86% |
Sanford C. Bernstein |
Portola Pharmaceuticals Inc. (South San Francisco; PTLA) |
10/17/13 |
$23.75 |
$25.75 |
$105.90 |
8% |
Sanford C. Bernstein |
Portola Pharmaceuticals Inc. (South San Francisco; PTLA) (IPO) |
5/22/13 |
$14.50 |
$25.75 |
$122.10 |
78% |
Stifel, Nicolaus & Co. |
Aerie Pharmaceuticals Inc. (Bedminster, N.J.; AERI) (IPO) (co-lead) |
10/28/13 |
$10.00 |
$17.96 |
$77.20 |
80% |
Stifel, Nicolaus & Co. |
Alcobra Ltd. (Tel Aviv, Israel; ADHD) (co-lead) |
10/25/13 |
$16.50 |
$18.00 |
$37.95 |
9% |
Stifel, Nicolaus & Co. |
Bind Therapeutics Inc. (Cambridge, Mass.; BIND) (IPO) |
9/20/13 |
$15.00 |
$15.09 |
$70.50 |
1% |
Stifel, Nicolaus & Co. |
Cempra Inc. (Chapel Hill, N.C.; CEMP) (co-lead) |
6/14/13 |
$7.00 |
$12.39 |
$57.75 |
77% |
Stifel, Nicolaus & Co. |
Chemocentryx Inc. (Mountain View, Calif.; CCXI) |
4/17/13 |
$12.00 |
$5.79 |
$60.00 |
-52% |
Stifel, Nicolaus & Co. |
Conatus Pharmaceuticals Inc. (San Diego; CNAT) (co-lead) (IPO) |
7/25/13 |
$11.00 |
$6.45 |
$66.00 |
-41% |
Stifel, Nicolaus & Co. |
Discovery Laboratories Inc. (Warrington, Pa.; DSCO) (co-lead) |
11/1/13 |
$2.00 |
$2.25 |
$50.00 |
13% |
Stifel, Nicolaus & Co. |
Discovery Laboratories Inc. (Warrington, Pa.; DSCO) (lead) |
5/13/13 |
$1.50 |
$2.25 |
$14.25 |
50% |
Stifel, Nicolaus & Co. |
Durect Corp. (Cupertino, Calif.; DRRX) (lead) |
11/8/13 |
$1.40 |
$1.73 |
$11.50 |
24% |
Stifel, Nicolaus & Co. |
Esperion Therapeutics Inc. (Plymouth, Mich.; ESPR) (IPO) |
6/26/13 |
$14.00 |
$13.74 |
$80.50 |
-2% |
Stifel, Nicolaus & Co. |
Isis Pharmaceuticals Inc. (Carlsbad, Calif.; ISIS) |
5/9/13 |
$19.00 |
$39.84 |
$182.70 |
110% |
Stifel, Nicolaus & Co. |
Keryx Biopharmaceuticals Inc. (New York; KERX) |
1/31/13 |
$8.49 |
$12.95 |
$69.90 |
53% |
Stifel, Nicolaus & Co. |
Macrogenics Inc. (Rockville, Md.; MGNX) (IPO) |
10/11/13 |
$16.00 |
$27.43 |
$92.00 |
71% |
Stifel, Nicolaus & Co. |
Mei Pharma Inc. (San Diego; MEIP) (co-lead) |
10/28/13 |
$8.00 |
$8.01 |
$35.00 |
0% |
Stifel, Nicolaus & Co. |
Mei Pharma Inc. (San Diego; MEIP) (co-lead) |
4/5/13 |
$7.50 |
$8.01 |
$15.20 |
7% |
Stifel, Nicolaus & Co. |
Newlink Genetics Corp. (Ames, Iowa; NLNK) |
1/31/13 |
$11.40 |
$22.01 |
$52.44 |
93% |
Stifel, Nicolaus & Co. |
Omthera Pharmaceuticals Inc.2 (Princeton, N.J.; OMTH) (IPO) |
4/12/13 |
$8.00 |
$12.70 |
$64.00 |
59% |
Stifel, Nicolaus & Co. |
Ophthotech Corp. (New York; OPHT) (IPO) |
9/25/13 |
$22.00 |
$32.35 |
$192.28 |
47% |
Stifel, Nicolaus & Co. |
Progenics Pharmaceuticals Inc. (Tarrytown, N.Y.; PGNX) |
6/21/13 |
$4.40 |
$5.33 |
$37.40 |
21% |
Stifel, Nicolaus & Co. |
Relypsa Inc. (Redwood City, Calif.; RLYP) (IPO) |
11/15/13 |
$11.00 |
$25.00 |
$85.80 |
127% |
Stifel, Nicolaus & Co. |
Sophiris Bio Inc. (San Diego; SPHS) (IPO) |
8/16/13 |
$5.00 |
$3.70 |
$65.00 |
-26% |
Stifel, Nicolaus & Co. |
Tekmira Pharmaceuticals Corp. (Vancouver, British Columbia; TKMR) (lead) |
10/18/13 |
$8.00 |
$7.97 |
$35.00 |
0% |
Stifel, Nicolaus & Co. |
Tetraphase Pharmaceuticals Inc. (Watertown, Mass.; TTPH) (IPO) |
3/20/13 |
$7.00 |
$13.52 |
$80.58 |
93% |
Stifel, Nicolaus & Co. |
Tetraphase Pharmaceuticals Inc. (Watertown, Mass; TTPH) (co-lead) |
11/4/13 |
$10.00 |
$13.52 |
$49.00 |
35% |
Stifel, Nicolaus & Co. |
Zogenix Inc. (San Diego; ZGNX) (co-lead) |
11/4/13 |
$2.25 |
$3.44 |
$68.85 |
53% |
Summer Street Research |
Rockwell Medical Inc. (Wixom, Mich.; RMTI) |
5/15/13 |
$3.05 |
$10.44 |
$40.30 |
242% |
Sunrise Securities Corp. |
Alcobra Ltd. (Tel Aviv, Israel; ADHD) (IPO) |
5/22/13 |
$8.00 |
$18.00 |
$25.00 |
125% |
Suntrust Robinson |
Acadia Pharmaceuticals Inc. (San Diego; ACAD) |
5/15/13 |
$12.50 |
$24.99 |
$115.00 |
100% |
Suntrust Robinson |
Cempra Inc. (Chapel Hill, N.C.; CEMP) |
6/14/13 |
$7.00 |
$12.39 |
$57.75 |
77% |
Suntrust Robinson |
Conatus Pharmaceuticals Inc. (San Diego; CNAT) (IPO) |
7/25/13 |
$11.00 |
$6.45 |
$66.00 |
-41% |
Trout Capital |
Prosensa Holding BV (Leiden, the Netherlands; RNA) (IPO) |
6/28/13 |
$13.00 |
$4.67 |
$89.70 |
-64% |
UBS Investment Bank |
Ariad Pharmaceuticals Inc. (Cambridge, Mass.; ARIA) |
1/24/13 |
$19.60 |
$6.82 |
$323.40 |
-65% |
UBS Investment Bank |
Intermune Inc. (Brisbane, Calif.; ITMN) |
11/6/13 |
$13.00 |
$14.73 |
$84.50 |
13% |
Wedbush Pacgrow Life Sci. |
Anacor Pharmaceuticals Inc. (Palo Alto, Calif.; ANAC) |
4/26/13 |
$6.39 |
$16.78 |
$23.00 |
163% |
Wedbush Pacgrow Life Sci. |
Bluebird Bio Inc. (Cambridge, Mass.; BLUE) (IPO) |
6/19/13 |
$17.00 |
$20.98 |
$116.11 |
23% |
Wedbush Pacgrow Life Sci. |
Celldex Therapeutics Inc. (Hampton, N.J.; CLDX) |
12/5/13 |
$24.50 |
$24.21 |
$191.40 |
-1% |
Wedbush Pacgrow Life Sci. |
Celldex Therapeutics Inc. (Needham, Mass.; CLDX) |
2/6/13 |
$7.50 |
$24.21 |
$103.50 |
223% |
Wedbush Pacgrow Life Sci. |
Cerus Corp. (Concord, Calif.; CERS) |
3/14/13 |
$4.20 |
$6.45 |
$35.00 |
54% |
Wedbush Pacgrow Life Sci. |
Epizyme Inc. (Cambridge, Mass.; EPZM) (IPO) |
5/31/13 |
$15.00 |
$20.80 |
$88.70 |
39% |
Wedbush Pacgrow Life Sci. |
Fate Therapeutics Inc. (San Diego; FATE) (IPO) |
10/1/13 |
$6.00 |
$6.28 |
$46.20 |
5% |
Wedbush Pacgrow Life Sci. |
Fibrocell Science Inc. (Exton, Pa.; FCSC) |
9/26/13 |
$4.10 |
$4.06 |
$50.43 |
-1% |
Wedbush Pacgrow Life Sci. |
Intercept Pharmaceuticals Inc. (New York; ICPT) |
6/19/13 |
$33.01 |
$68.28 |
$65.69 |
107% |
Wedbush Pacgrow Life Sci. |
Macrogenics Inc. (Rockville, Md.; MGNX) (IPO) |
10/11/13 |
$16.00 |
$27.43 |
$92.00 |
71% |
Wedbush Pacgrow Life Sci. |
Mei Pharma Inc. (San Diego; MEIP) |
10/28/13 |
$8.00 |
$8.01 |
$35.00 |
0% |
Wedbush Pacgrow Life Sci. |
Novavax Inc. (Rockville, Md.; NVAX) |
9/24/13 |
$3.14 |
$5.12 |
$99.85 |
63% |
Wedbush Pacgrow Life Sci. |
Oncolytics Biotech Inc. (Calgary, Alberta; ONCY) (co-lead) |
2/21/13 |
$4.00 |
$1.55 |
$32.00 |
-61% |
Wedbush Pacgrow Life Sci. |
Prosensa Holding BV (Leiden, the Netherlands; RNA) (IPO) |
6/28/13 |
$13.00 |
$4.67 |
$89.70 |
-64% |
Wedbush Pacgrow Life Sci. |
Prothena Corp. plc (Dublin; PRTA) |
10/13/13 |
$22.00 |
$26.52 |
$77.00 |
21% |
Wedbush Pacgrow Life Sci. |
PTC Therapeutics Inc. (South Plainfield, N.J.; PTCT) (IPO) |
6/20/13 |
$15.00 |
$16.97 |
$144.48 |
13% |
Wedbush Pacgrow Life Sci. |
Receptos Inc. (San Diego; RCPT) (IPO) |
5/9/13 |
$14.00 |
$28.99 |
$72.80 |
107% |
Wedbush Pacgrow Life Sci. |
Regado Biosciences Inc. (Basking Ridge, N.J.; RGDO) (IPO) |
8/22/13 |
$4.00 |
$4.77 |
$46.68 |
19% |
Wedbush Pacgrow Life Sci. |
Regulus Therapeutics Inc. (La Jolla, Calif.; RGLS) |
7/17/13 |
$9.50 |
$7.39 |
$49.20 |
-22% |
Wedbush Pacgrow Life Sci. |
Relypsa Inc. (Redwood City, Calif.; RLYP) (IPO) |
11/15/13 |
$11.00 |
$25.00 |
$85.80 |
127% |
Wedbush Pacgrow Life Sci. |
Xencor Inc. (Redwood City, Calif.; XNCR) (IPO) (co-lead) |
12/3/13 |
$5.50 |
$9.14 |
$80.30 |
66% |
Wells Fargo Securities |
Achillion Pharmaceuticals Inc. (New Haven, Conn.; ACHN) |
3/1/13 |
$8.40 |
$3.32 |
$141.96 |
-60% |
Wells Fargo Securities |
Biocryst Pharmaceuticals Inc. (Research Triangle Park, N.C.; BCRX) (co-lead) |
8/2/13 |
$4.40 |
$7.60 |
$20.20 |
73% |
Wells Fargo Securities |
Five Prime Therapeutics Inc. (South San Francisco; FPRX) (co-lead) (IPO) |
9/18/13 |
$13.00 |
$16.79 |
$71.80 |
29% |
Wells Fargo Securities |
Insys Therapeutics Inc. (Phoenix; INSY) (co-lead) (IPO) |
5/2/13 |
$8.00 |
$38.71 |
$32.00 |
384% |
Wells Fargo Securities |
Intermune Inc. (Brisbane, Calif.; ITMN) |
11/6/13 |
$13.00 |
$14.73 |
$84.50 |
13% |
Wells Fargo Securities |
Intermune Inc. (Brisbane, Calif.; ITMN) |
1/16/13 |
$9.90 |
$14.73 |
$133.65 |
49% |
Wells Fargo Securities |
Zogenix Inc. (San Diego; ZGNX) (co-lead) |
11/4/13 |
$2.25 |
$3.44 |
$68.85 |
53% |
William Blair & Co. |
Biodel Inc. (Danbury, Conn.; BIOD) (lead) |
6/20/13 |
$4.35 |
$2.28 |
$19.49 |
-48% |
William Blair & Co. |
Chimerix Inc. (Research Triangle Park, N.C.; CMRX) (IPO) |
4/11/13 |
$14.00 |
$15.11 |
$102.50 |
8% |
William Blair & Co. |
Dynavax Technologies Corp. (Berkeley, Calif.; DVAX) |
10/25/13 |
$1.08 |
$1.96 |
$132.20 |
82% |
William Blair & Co. |
Intermune Inc. (Brisbane, Calif.; ITMN) |
1/16/13 |
$9.90 |
$14.73 |
$133.65 |
49% |
William Blair & Co. |
Kalobios Pharmaceuticals Inc. (South San Francisco; KBIO) |
9/26/13 |
$4.00 |
$4.42 |
$30.00 |
11% |
William Blair & Co. |
Kalobios Pharmaceuticals Inc. (South San Francisco; KBIO) (IPO) |
1/31/13 |
$8.00 |
$4.42 |
$70.00 |
-45% |
William Blair & Co. |
Portola Pharmaceuticals Inc. (South San Francisco; PTLA) |
10/17/13 |
$23.75 |
$25.75 |
$105.90 |
8% |
William Blair & Co. |
Portola Pharmaceuticals Inc. (South San Francisco; PTLA) (IPO) |
5/22/13 |
$14.50 |
$25.75 |
$122.10 |
78% |
William Blair & Co. |
Ventrus Biosciences Inc. (New York; VTUS) (lead) |
2/4/13 |
$2.50 |
$3.82 |
$22.20 |
53% |
William Blair & Co. |
Zogenix Inc. (San Diego; ZGNX) |
11/4/13 |
$2.25 |
$3.44 |
$68.85 |
53% |
|
Notes *The financings in this chart are for public offerings in the U.S. only. They do not include offerings of convertible senior notes or at-the-market offerings. They do not include public offerings in which there were no underwriters. The data were compiled primarily from BioWorld Insight’s monthly financing charts covering the period from Jan. 1 to Dec. 31 , 2013. The gross proceed totals listed reflect only those shares sold by companies. They include money raised through overallotment options, when disclosed. ** All prices are in U.S. dollars. Offering price per share is adjusted to reflect any post-offering splits. Unless otherwise noted, shares are traded on the Nasdaq exchange. NYSE = New York Stock Exchange. OTCQB = Over-the-Counter; AMEX = American Stock Exchange. IPO = Initial Public Offering 1 Oxygen Biotherapeutics offered 5,369 units at $1 ,000 each, consisting of 2.75M shares at $1 .95 per share. 2 Omthera’s Dec. 31 , 2013, stock price listed is the price, $12.70 per share, in which Astrazeneca plc agreed to acquire the company. 3 Aastrom’s offering price listed accounts for a 1-for-20 stock split that occurred on Oct. 16, 2013. 4 Neostem’s offering price listed accounts for a 1-for-10 stock split that occurred on July 16, 2013. 5 Oculus’ offering price listed accounts for a 1-for-7 stock split that occurred on April 1, 2013. 6 Anthera’s offering price listed accounts for a 1-for-8 stock split that occurred on July 15, 2013. 7 Cubist Pharmaceuticals Inc. acquired Trius in September 2013. The final stock price occurred on Sept. 11, 2013. 8 Onyx’s Dec. 31, 2013, stock price listed is the price, $125 per share, for which Amgen Inc. acquired the company in August 2013. | ||||||
